Komori
Governance4886ASKA Pharmaceutical Holdings Co.,Ltd.Pharmaceuticals

Revision of the restricted stock compensation plan for directors (excluding outside directors and directors who are Audit and Supervisory Committee members), and the transfer to outside directors (excluding outside directors who are Audit and Supervisory Committee members)

Subject to the transition to a company with an Audit and Supervisory Committee, the restricted stock compensation for directors will be reviewed and a performance-linked plan will be introduced. In addition, service-based stock compensation will be introduced for outside directors who are not Audit and Supervisory Committee members.

Worth reading
50Recurring
Scored from 1 of 5 sections
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
140
¥ million (annual total amount for Eligible Directors ①)
Wording
Conditional
How definitive the wording is.

Governance structure

Company with an Audit and Supervisory Committee (planned transition subject to approval at the shareholders meeting scheduled for 24 June 2026)
Committee1
Audit and Supervisory Committee. The proportion of outside members is not disclosed. The Nomination and Compensation Committee is not disclosed.
Changes this time

Subject to the transition to a company with an Audit and Supervisory Committee, the service-based restricted stock compensation plan will be partially revised and a performance-based plan will be introduced. A service-based restricted stock compensation plan will also be introduced for outside directors who are not Audit and Supervisory Committee members. Both measures are subject to approval at the shareholders meeting.

Governance structure
ItemDetails
Corporate Governance StructureCompany with an Audit and Supervisory Committee (planned transition subject to approval at the shareholders meeting scheduled for 24 June 2026)
CommitteeAudit and Supervisory Committee. The proportion of outside members is not disclosed. The Nomination and Compensation Committee is not disclosed.
Changes this timeSubject to the transition to a company with an Audit and Supervisory Committee, the service-based restricted stock compensation plan will be partially revised and a performance-based plan will be introduced. A service-based restricted stock compensation plan will also be introduced for outside directors who are not Audit and Supervisory Committee members. Both measures are subject to approval at the shareholders meeting.
Items this document does not state (5)
Number of directorsNumber of independent officersPolicy on cross-shareholdingsTakeover defensesControlling shareholder

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To promote the sharing of value with shareholders and provide incentives for sustained enhancement of corporate value. In addition, to strengthen the linkage between compensation and performance for Eligible Directors ①, and to enable outside directors to fully exercise their oversight function over management aimed at enhancing corporate value.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Revision of the restricted stock compensation plan for directors (excluding outside directors and directors who are Audit and Supervisory Committee members), and the transfer to outside directors (excluding outside directors who are Audit and Supervisory Committee members) | ASKA Pharmaceutical Holdings Co.,Ltd. (4886) timely disclosure | Komori